Nizatidine

Nizatidine
Clinical data
Trade names	Axid, Tazac
AHFS/Drugs.com	Monograph
MedlinePlus	a694030
License data	US DailyMed: Nizatidine;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
ATC code	A02BA04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / OTC; UK: POM (Prescription only); US: OTC / Rx-only;
Pharmacokinetic data
Bioavailability	>70%
Protein binding	35%
Metabolism	Liver
Elimination half-life	1–2 hours
Excretion	Kidney
Identifiers
	IUPAC name (E)-1-N'-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine;
CAS Number	76963-41-2 ;
PubChem CID	3033637;
IUPHAR/BPS	7248;
DrugBank	DB00585 ;
ChemSpider	2298266 ;
UNII	P41PML4GHR;
KEGG	D00440 ;
ChEBI	CHEBI:7601 ;
ChEMBL	ChEMBL653 ;
CompTox Dashboard (EPA)	DTXSID5023376 ;
ECHA InfoCard	100.155.683
Chemical and physical data
Formula	C12H21N5O2S2
Molar mass	331.45 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [O-][N+](=O)\C=C(/NC)NCCSCc1nc(sc1)CN(C)C;
	InChI InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+ ; Key:SGXXNSQHWDMGGP-IZZDOVSWSA-N ;
	(what is this?) (verify)

Nizatidine is a histamine H₂ receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.

It was patented in 1980 and approved for medical use in 1988. It was developed by Eli Lilly.